539 related articles for article (PubMed ID: 19117996)
21. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
Kim J; Park H; Im JY; Choi WS; Kim HS
Anticancer Res; 2007; 27(5A):3285-92. PubMed ID: 17970072
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.
Tepper CG; Boucher DL; Ryan PE; Ma AH; Xia L; Lee LF; Pretlow TG; Kung HJ
Cancer Res; 2002 Nov; 62(22):6606-14. PubMed ID: 12438256
[TBL] [Abstract][Full Text] [Related]
23. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
24. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
25. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
26. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
27. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
28. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.
Agoulnik IU; Vaid A; Bingman WE; Erdeme H; Frolov A; Smith CL; Ayala G; Ittmann MM; Weigel NL
Cancer Res; 2005 Sep; 65(17):7959-67. PubMed ID: 16140968
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis.
Takayama K; Kaneshiro K; Tsutsumi S; Horie-Inoue K; Ikeda K; Urano T; Ijichi N; Ouchi Y; Shirahige K; Aburatani H; Inoue S
Oncogene; 2007 Jun; 26(30):4453-63. PubMed ID: 17297473
[TBL] [Abstract][Full Text] [Related]
31. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
Eder IE; Haag P; Basik M; Mousses S; Bektic J; Bartsch G; Klocker H
Mol Carcinog; 2003 Aug; 37(4):181-91. PubMed ID: 12891627
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.
Sampson ER; Yeh SY; Chang HC; Tsai MY; Wang X; Ting HJ; Chang C
J Biol Regul Homeost Agents; 2001; 15(2):123-9. PubMed ID: 11501969
[TBL] [Abstract][Full Text] [Related]
33. The role of the androgen receptor in the development and progression of prostate cancer.
Jenster G
Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
[TBL] [Abstract][Full Text] [Related]
34. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
35. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
[TBL] [Abstract][Full Text] [Related]
36. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
37. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers.
Ren G; Zhang G; Dong Z; Liu Z; Li L; Feng Y; Su D; Zhang Y; Huang B; Lu J
Int J Biochem Cell Biol; 2009 May; 41(5):1094-101. PubMed ID: 19013255
[TBL] [Abstract][Full Text] [Related]
38. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK
Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320
[TBL] [Abstract][Full Text] [Related]
39. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.
Koochekpour S; Lee TJ; Wang R; Sun Y; Delorme N; Hiraiwa M; Grabowski GA; Culig Z; Minokadeh A
J Cell Biochem; 2007 Jun; 101(3):631-41. PubMed ID: 17171640
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor and invasion in prostate cancer.
Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]